
Shattuck Labs Investor Relations Material
Latest events

Study Update
Shattuck Labs

Corporate Presentation
1 May, 2025

Q1 2025
30 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Shattuck Labs Inc
Access all reports
Shattuck Labs Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create biologic therapies that enhance the body's immune response. Shattuck Labs' technology is designed to modulate immune pathways, potentially improving outcomes for patients with challenging conditions. The company is involved in research and development efforts, advancing its immunotherapy candidates through clinical trials. The company is headquartered in Durham, North Carolina, and its shares are listed on the NASDAQ.
Key slides for Shattuck Labs Inc


Study Update
Shattuck Labs Inc


Study Update
Shattuck Labs Inc
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
STTK
Country
🇺🇸 United States